Brett P. Monia, PhD
About Brett P. Monia, PhD
Brett P. Monia, Ph.D., is the CEO with a strong background in pharmacology and molecular biology, holding multiple patents and having published extensively in his field.
Brett P. Monia, Ph.D. - Chief Executive Officer
Brett P. Monia, Ph.D., serves as the Chief Executive Officer, bringing a wealth of experience in pharmacology and molecular biology. His leadership role places him at the helm of guiding strategic decisions and organizational growth. His academic background and extensive experience have shaped his leadership approach, making significant contributions to the field.
Brett P. Monia, Ph.D. - Education and Expertise
Brett P. Monia received his Ph.D. in Pharmacology from the University of Pennsylvania. He also holds B.S. degrees in Molecular Biology and Analytical Chemistry from Stockton State College in Pomona, New Jersey. His academic background laid a strong foundation for his career in pharmacology, emphasizing molecular and analytical techniques critical to his field.
Brett P. Monia, Ph.D. - Publications and Patents
Brett P. Monia has published more than 200 primary research manuscripts, reviews, and book chapters. His prolific publication record demonstrates his extensive research in pharmacology, contributing to scientific literature and knowledge. Additionally, he is an inventor on over 100 issued patents, reflecting his innovative contributions to the field and the practical applications of his research.
Brett P. Monia, Ph.D. - Academic and Editorial Roles
Brett P. Monia serves as a senior editor for the journal Nucleic Acid Therapeutics. He also holds an adjunct professorship in biology at San Diego State University, where he lectures at the graduate level on pharmacology. His roles in academia and editorial responsibilities highlight his commitment to educating future scientists and advancing scientific communication.
Brett P. Monia, Ph.D. - Board Memberships
Brett P. Monia is on the board of directors of Cognition Therapeutics and Flamingo Therapeutics. His involvement with these organizations indicates his active engagement in the broader scientific and business communities, contributing his expertise to guide these companies strategically. His board memberships also reflect his prominence and respect within the industry.